Allergy Therapeutics plc has announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, where it will be presenting key scientific findings from its research portfolio. The company will be sharing positive results from the pivotal Phase III G306 trial, which evaluated the efficacy and safety of Grass MATA MPL, its short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate for allergic rhinoconjunctivitis due to grass pollen. These findings will support the Group's marketing authorization application (MAA), with a planned submission in Q4 2024.

Additionally, Allergy Therapeutics will present results from the analysis of patient and caregiver preferences for different venom and pollen immunotherapy approaches, as well as the safety and tolerability results from the healthy subject subcutaneous dosing cohorts of the Phase I/IIa PROTECT trial of its novel virus-like-particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut"). The company will also host a symposium on "Setting a new standard for grass subcutaneous immunotherapy," featuring presentations covering regulatory and clinical challenges in allergen immunotherapy trials, as well as results from the pivotal Phase III G306 trial of Grass MATA MPL by key experts from the US and EU.

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, expressed excitement about the company's robust presence at the EAACI Congress, stating that the research being shared demonstrates the strength of their science. He emphasized the company's commitment to helping patients change the way they think about their allergies and better manage their conditions.

The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation is available on the Group's website. The company also confirmed that no new material price-sensitive information is expected to be disclosed at the EAACI Congress 2024.

In conclusion, Allergy Therapeutics' participation in the EAACI Congress 2024 underscores its dedication to advancing immunology treatments and its mission to transform lives by providing innovative solutions for allergy management.